Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

@article{Hartwell2011PeginterferonAA,
  title={Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.},
  author={Debbie Hartwell and Jeremy A Jones and Louise Baxter and Jessica Shepherd},
  journal={Health technology assessment},
  year={2011},
  volume={15 17},
  pages={i-xii, 1-210}
}
OBJECTIVE to assess the clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis c virus (HCV) in three specific patient subgroups affected by recent licence changes: those eligible for shortened treatment courses [i.e. those with low viral load (LVL) and who attained a rapid virological response (RVR) at 4 weeks of treatment], those eligible for re-treatment following previous non-response or relapse, and those co-infected with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 105 references

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment , retreatment or in HCV / HIV co - infection : a systematic review and economic evaluation

  • D Hartwell, J Jones, L Baxter, J Shepherd
  • Health Technol Assess
  • 2011

Sustained viral response (SVR) is dependent on baseline characteristics in the re-treatment of previous alfa interferon/ribavirin (I/R) nonresponders (NR): final results from the EPIC3 program

  • T Poynard, E Schiff, R Terg, R Moreno Otero, S Flamm, W Schmidt
  • Health Technology Assessment
  • 2011

Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis

  • AA Stinnett
  • Med Dec Making 2009;18:S68–80
  • 2009

Pegylated interferon alfa-2b and ribavirin for hepatitis C: re-treatment of patients previously failing therapy and treatment of HIV/HCV co-infected patients

  • Schering-Plough Ltd
  • NICE MTA submission,
  • 2009

Summary of Product Characteristics – Peginterferon alfa-2a (Pegasys)

  • UK Roche
  • Electronic Medicines Compendium
  • 2009

Similar Papers

Loading similar papers…